References
- da Silva SD, Ferlito A, Takes RP, et al. (2011). Advances and applications of oral cancer basic research. Oral Oncol 47:783–91
- Deng R, Hao J, Han W, et al. (2015). Gelsolin regulates proliferation, apoptosis, migration and invasion in human oral carcinoma cells. Oncol Lett 9:2129–34
- Dominguez R. (2004). Actin-binding proteins-a unifying hypothesis. Trends Biochem Sci 29:572–8
- dos Remedios CG, Chhabra D, Kekic M, et al. (2003). Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83:433–73
- Dosaka-Akita H, Hommura F, Fujita H, et al. (1998). Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58:322–7
- Janmey PA, Chaponnier C. (1995). Medical aspects of the actin cytoskeleton. Curr Opin Cell Biol 7:111–17
- Kim JH, Choi YK, Kwon HJ, et al. (2004). Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19:218–24
- Li GH, Arora PD, Chen Y, et al. (2012). Multifunctional roles of gelsolin in health and diseases. Med Res Rev 32:999–1025
- Liao CJ, Wu TI, Huang YH, et al. (2011). Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance. Gynecol Oncol 120:135–44
- Messadi DV. (2013). Diagnostic aids for detection of oral precancerous conditions. Int J Oral Sci 5:59–65
- Ni XG, Zhou L, Wang GQ, et al. (2008). The ubiquitin-proteasome pathway mediates gelsolin protein downregulation in pancreatic cancer. Mol Med 14:582–9
- Noske A, Denkert C, Schober H, et al. (2005). Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 41:461–9
- Petersen PE. (2009). Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 45:454–60
- Pollard TD, Borisy GG. (2003). Cellular motility driven by assembly and disassembly of actin filaments. Cell 112:453–65
- Robinson PN, Mickelson AR. (2006). Early diagnosis of oral cavity cancers. Otolaryngol Clin North Am 39:295–306
- Sciubba JJ. (2001). Oral cancer. The importance of early diagnosis and treatment. Am J Clin Dermatol 2:239–51
- Shieh DB, Chen IW, Wei TY, et al. (2006). Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 42:599–606
- Shieh DB, Godleski J, Herndon JEII, et al. (1999). Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 85:47–57
- Siegel R, Ma J, Zou Z, Jemal A. (2014). Cancer statistics, 2014. CA Cancer J Clin 64:9–29
- Stadler ME, Patel MR, Couch ME, Hayes DN. (2008). Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am 22:1099–124
- Tanaka M, Müllauer L, Ogiso Y, et al. (1995). Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55:3228–32
- Tsantoulis PK, Kastrinakis NG, Tourvas AD, et al. (2007). Advances in the biology of oral cancer. Oral Oncol 43:523–34
- Uribe R, Jay D. (2009). A review of actin binding proteins: new perspectives. Mol Biol Rep 36:121–5
- Winder SJ, Ayscough KR. (2005). Actin-binding proteins. J Cell Sci 118:651–4
- Winston JS, Asch HL, Zhang PJ, et al. (2001). Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 65:11–21